MediciNova, Inc.
Supplementary Earnings Presentation
Consolidated results for Q3 of the fiscal year ending December 2026 remained in deficit. Revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. R&D expenses were 557,766 thousand yen and general & administrative expenses were 832,951 thousand yen. Cash and cash equivalents were approx. 29,256,294 thousand yen, and total liabilities were approx. 4,147,795 thousand USD equivalent. Ongoing clinical trials include ALS, diabetes-related NAFLD, CCA, etc., with planned data releases and topline announcements.
Key Figures
- Revenue: 123,507 thousand yen
- Operating Income: -1,329,199 thousand yen
- Net Income Attributable to Owners of Parent: -1,219,888 thousand yen
AI要約
Overview of Results
For Q3 of the fiscal year ending December 2026, revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. Research and development expenses were 557,766 thousand yen and general and administrative expenses were 832,951 thousand yen, reflecting a continued cost structure weighted toward R&D and administrative spending. Cash and cash equivalents remain substantial at approximately 29,256,294 thousand yen.
R&D Progress and Outlook
Multiple clinical trials centered on ALS are ongoing. Several data disclosures have been announced, including COMBAT-ALS (Phase 2b/3), SEANOBI-ALS, the MN-166 (ibudilast) related Expanded Access Program, and topline results for MN-001-NATG-202 for type 2 diabetes-related indications. Final evaluations and related results are expected to be disclosed around February 2027.
Revenue Trend
Operating Income Trend
MediciNova, Inc.
Company overview · Stock price · Financial data · All IR
